Brokerages Set Insulet Co. (NASDAQ:PODD) Price Target at $239.18

Shares of Insulet Co. (NASDAQ:PODD) have been assigned a consensus rating of “Moderate Buy” from the eighteen research firms that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and fifteen have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $239.18.

PODD has been the subject of a number of analyst reports. Wolfe Research upgraded shares of Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price objective for the company in a research note on Tuesday, May 7th. Jefferies Financial Group increased their target price on Insulet from $255.00 to $260.00 and gave the company a “buy” rating in a research note on Friday, May 10th. OTR Global reaffirmed a “mixed” rating on shares of Insulet in a research report on Monday, June 10th. Canaccord Genuity Group reissued a “buy” rating and issued a $234.00 price objective on shares of Insulet in a research report on Tuesday. Finally, Barclays dropped their target price on shares of Insulet from $213.00 to $200.00 and set an “equal weight” rating on the stock in a research report on Monday, May 13th.

Insulet Stock Up 1.3 %

Insulet stock opened at $193.30 on Monday. The company has a current ratio of 3.74, a quick ratio of 2.75 and a debt-to-equity ratio of 1.72. Insulet has a 1-year low of $125.82 and a 1-year high of $283.00. The firm’s fifty day simple moving average is $193.24 and its 200-day simple moving average is $184.74. The company has a market capitalization of $13.54 billion, a P/E ratio of 58.58, a P/E/G ratio of 3.50 and a beta of 1.16.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.34. The company had revenue of $441.70 million for the quarter, compared to analyst estimates of $424.05 million. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The business’s revenue was up 23.3% compared to the same quarter last year. During the same period last year, the company earned $0.23 earnings per share. Sell-side analysts forecast that Insulet will post 3.11 earnings per share for the current fiscal year.

Insider Buying and Selling at Insulet

In related news, SVP Mark N. Field sold 1,500 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $199.96, for a total transaction of $299,940.00. Following the completion of the sale, the senior vice president now directly owns 12,875 shares of the company’s stock, valued at $2,574,485. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Insulet news, SVP Mark N. Field sold 1,500 shares of Insulet stock in a transaction on Friday, June 14th. The shares were sold at an average price of $199.96, for a total transaction of $299,940.00. Following the completion of the sale, the senior vice president now owns 12,875 shares of the company’s stock, valued at approximately $2,574,485. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Timothy J. Scannell sold 7,000 shares of the stock in a transaction on Monday, June 10th. The shares were sold at an average price of $190.51, for a total value of $1,333,570.00. Following the completion of the transaction, the director now directly owns 35,586 shares in the company, valued at approximately $6,779,488.86. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,931 shares of company stock worth $2,636,286. Company insiders own 0.47% of the company’s stock.

Hedge Funds Weigh In On Insulet

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Consolidated Portfolio Review Corp raised its holdings in Insulet by 1.6% in the fourth quarter. Consolidated Portfolio Review Corp now owns 3,713 shares of the medical instruments supplier’s stock worth $806,000 after purchasing an additional 57 shares during the period. FourThought Financial Partners LLC lifted its holdings in Insulet by 1.4% during the fourth quarter. FourThought Financial Partners LLC now owns 4,461 shares of the medical instruments supplier’s stock worth $968,000 after acquiring an additional 61 shares in the last quarter. Linden Thomas Advisory Services LLC grew its stake in Insulet by 1.3% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 5,817 shares of the medical instruments supplier’s stock valued at $1,262,000 after acquiring an additional 73 shares during the period. Lindbrook Capital LLC grew its stake in Insulet by 64.1% in the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock valued at $42,000 after acquiring an additional 75 shares during the period. Finally, Moody National Bank Trust Division increased its holdings in shares of Insulet by 2.6% in the first quarter. Moody National Bank Trust Division now owns 3,439 shares of the medical instruments supplier’s stock worth $589,000 after acquiring an additional 87 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.